Thursday, March 10, 2011
Clinical proof of concept patient trials for OX1 in Friedreich's Ataxia
Intellect Neurosciences, Inc. is a Manhattan-based biopharmaceutical company
The Company's most advanced internally developed product is OX1 which has been tested in Phase 1 clinical trials. The Company plans to conduct clinical proof of concept patient trials for OX1 in Alzheimer's disease and Friedreich's Ataxia,
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment